Musings from The Power List: Ann Cleves
Ann Cleves on why the future of small-molecule drug discovery lies beyond the rule of five
-
By
-
Ann Cleeves
-
August 11, 2026
-
-
1
Ann Cleves highlights advancements in macrocyclic peptide research, particularly through collaboration with Merck.
-
2
Recent work published in JCIM demonstrates methods for conformational analysis of macrocyclic peptides using NMR data.
-
3
Small molecules retain advantages in drug optimization, including oral dosing and computational modeling capabilities.
-
4
Cleves challenges the belief that existing drugs can easily address unmet therapeutic needs, emphasizing the need for novel compounds.
-
5
She argues that drug repurposing and AI models have limitations in addressing complex therapeutic challenges.
